In fact, natural β-CyD has a toxic effect on kidney, which is the main organ for the removal of CyDs from
the systemic circulation and for concentrating CyDs in the proximal convoluted tubule after glomerular filtration [14]. Actually, amorphous mixtures of highly water-soluble β-CyDs such as HP-β-CyD and SBE-β-CyD have very low systemic toxicity, compared with β-CyD. We previously reported the effects of hydrophilic β-CyDs on the aggregation of bovine insulin in aqueous solution and Inhibitors,research,lifescience,medical its adsorption onto hydrophilic surfaces [15–17]. Of the CyDs tested, G2-β-CyD potently inhibited insulin aggregation in a neutral solution and its adsorption onto the surfaces of glass and MK0683 cell line polypropylene tubes. In addition,
SBE-β-CyDs showed different effects on insulin aggregation Inhibitors,research,lifescience,medical in phosphate buffer (pH 6.8, I = 0.2), depending on the degree of substitution (DS) of the sulfobutyl ether group, SBE4-β-CyD (DS = 3.9) showed deceleration of insulin aggregation, and SBE7-β-CyD (DS = 6.2) showed Inhibitors,research,lifescience,medical acceleration [17]. Furthermore, we reported that after subcutaneous administration of insulin solution to rats, SBE4-β-CyD rapidly increased plasma insulin level and maintained higher plasma insulin levels for at least 8h, possibly due to the inhibitory effects of SBE4-β-CyD on the enzymatic degradation and/or the adsorption of insulin onto the subcutaneous tissue at the injection site [18]. More recently, we have demonstrated that SBE4-β-CyD enhanced both bioavailability and prolonged the blood-glucose lowering effect of insulin glargine after subcutaneous administration to rats, probably due to the inhibitory effects of interaction with SBE4-β-CyD on the enzymatic degradation at the injection site [19]. Inhibitors,research,lifescience,medical However, it is still unknown whether other anionic β-CyD derivatives such as Sul-β-CyD and SBE7-β-CyD show the improved bioavailability and sustained-glucose lowering effects for insulin glargine. Therefore, the objective in the present study is to evaluate the
potential use of anionic β-CyD derivatives, Inhibitors,research,lifescience,medical such as Sul-β-CyD and SBE7-β-CyD, on not only bioavailability Rocilinostat molecular weight of insulin glargine but also the sustained-blood-glucose lowering effects. In addition, the effects of Sul-β-CyD and SBE7-β-CyD on physicochemical properties and pharmacokinetics/pharmacodynamics of insulin glargine were examined. 2. Materials and Methods 2.1. Materials Insulin glargine was supplied by Sanofi-Aventis (Paris, France). SBE7-β-CyD was provided by CyDex (Kansas, USA). Sul-β-CyD with an average degree of substitution of 10.7 was prepared by a nonregional selective method as described previously [20]. Recombinant trypsin (EC 3.4.21.4) of proteomics grade was purchased from Roche Diagnostics (Tokyo, Japan). Phosphate buffer (pH 9.5, I = 0.2) was prepared according to the US Pharmacopeia; 0.